Home » INDEVUS INITIATES PHASE III CLINICAL PROGRAM FOR SANCTURA XR IN OVERACTIVE BLADDER
INDEVUS INITIATES PHASE III CLINICAL PROGRAM FOR SANCTURA XR IN OVERACTIVE BLADDER
Indevus Pharmaceuticals has initiated a Phase III clinical program for Sanctura XR in patients with overactive bladder. Sanctura XR is the once-daily formulation of Sanctura, which is currently being marketed in the U.S.
The program consists of two 12-week, double-blind, placebo-controlled studies totaling 1,200 adults at approximately 120 sites in the U.S. The objective of the trials is to evaluate the effects of once-daily dosing of trospium chloride on urinary frequency, urge incontinence and other related symptoms associated with overactive bladder.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May